Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
There are nonpharmacological approaches to managing behavioral and psychological symptoms of dementia and the difficulties associated with evaluating and implementing these approaches.
Laura N. Gitlin, PhD and Nancy A. Hodgson, PhD, RN
As a matter of medical ethics, physicians must address the health care needs of and be advocates for family caregivers of their patients with dementia.
AMA J Ethics. 2016;18(12):1171-1181. doi:
10.1001/journalofethics.2016.18.12.ecas1-1612.
B. Rashmi Borah, Nicolle K. Strand, JD, MBioethics, and Kata L. Chillag, PhD
The Bioethics Commission’s recommendations to include research participants with impaired consent capacity provide an ethical foundation for neuroscience.
AMA J Ethics. 2016;18(12):1192-1198. doi:
10.1001/journalofethics.2016.18.12.nlit1-1612.
The need for improved health care transition (HCT) for youth with autism spectrum disorder (ASD) can be met with training for health care professionals, financial counseling for parents of children with ASD, and increased vocational training and opportunities for youth with ASD.
AMA J Ethics. 2015;17(4):342-347. doi:
10.1001/journalofethics.2015.17.4.pfor1-1504.